Fujihara Mitsuhiro, Muroi Masashi, Tanamoto Ken-ichi, Suzuki Tsuneo, Azuma Hiroshi, Ikeda Hisami
Japanese Red Cross, Hokkaido Red Cross Blood Center, Yamanote 2-2, Nishi-ku, Sapporo 063-0002, Japan.
Pharmacol Ther. 2003 Nov;100(2):171-94. doi: 10.1016/j.pharmthera.2003.08.003.
Bacterial lipopolysaccharide (LPS), the major structural component of the outer wall of Gram-negative bacteria, is a potent activator of macrophages. Activated macrophages produce a variety of inflammatory cytokines. Excessive production of cytokines in response to LPS is regarded as the cause of septic shock. On the other hand, macrophages exposed to suboptimal doses of LPS are rendered tolerant to subsequent exposure to LPS and manifest a profoundly altered response to LPS. Increasing evidence suggests that monocytic cells from patients with sepsis and septic shock survivors have characteristics of LPS tolerance. Thus, an understanding of the molecular mechanisms underlying activation and deactivation of macrophages in response to LPS is important for the development of therapeutics for septic shock and the treatment of septic shock survivors. Over the past several years, significant progress has been made in identifying and characterizing several key molecules and signal pathways involved in the regulation of macrophage functions by LPS. In this paper, we summarize the current findings of the functions of the LPS receptor complex, which is composed of CD14, Toll-like receptor 4 (TLR4), and myeloid differentiation protein-2 (MD-2), and the signal pathways of this LPS receptor complex with regard to both activation and deactivation of macrophages by LPS. In addition, recent therapeutic approaches for septic shock targeting the LPS receptor complex are described.
细菌脂多糖(LPS)是革兰氏阴性菌外壁的主要结构成分,是巨噬细胞的强效激活剂。活化的巨噬细胞会产生多种炎性细胞因子。对LPS产生的细胞因子过度产生被认为是脓毒症休克的原因。另一方面,暴露于次优剂量LPS的巨噬细胞会对随后暴露于LPS产生耐受,并表现出对LPS的反应发生深刻改变。越来越多的证据表明,脓毒症患者和脓毒症休克幸存者的单核细胞具有LPS耐受的特征。因此,了解巨噬细胞对LPS反应的激活和失活的分子机制对于开发脓毒症休克治疗方法和治疗脓毒症休克幸存者至关重要。在过去几年中,在鉴定和表征参与LPS调节巨噬细胞功能的几个关键分子和信号通路方面取得了重大进展。在本文中,我们总结了由CD14、Toll样受体4(TLR4)和髓样分化蛋白2(MD-2)组成的LPS受体复合物功能的当前研究结果,以及该LPS受体复合物在LPS激活和失活巨噬细胞方面的信号通路。此外,还描述了针对LPS受体复合物的脓毒症休克近期治疗方法。